SIBN · SI-BONE

The thesis

SI-BONE's recovery case holds, and the shares have a modest edge over the S&P 500 into the fourth-quarter report in late February. That report settles the case: management said on the 2 November 2026 earnings call that the midpoint of its $231–233 million 2026 revenue outlook implies more than 20% fourth-quarter growth. The company beat third-quarter estimates on 2 November 2026 and reaffirmed the outlook. It also gets a final Medicare office payment for sacroiliac joint fusion from 1 January 2027.

The price already reflects that the outlook will be met. The shares closed at $24.14 on 12 November 2026, above TD Cowen's $23 target and below the $26 targets from UBS and Needham (all 3 November 2026) and BofA Securities' $29 target (10 November 2026). At the UBS Global Healthcare Conference on 10 November 2026, the chief operating and financial officer declined to give 2027 guidance until the company sees fourth- and first-quarter results, Investing.com reported.

The shares have pulled back from the $25.60 close of 9 November 2026 to $24.14 over three sessions. No new company results, guidance or analyst action came with that move. Management has pointed to late February for fourth-quarter results, and no other company event is scheduled before then.

Bullish and bearish views on SI-BONE, Inc.

The bull case on SI-BONE, Inc. (SIBN), in brief: third-quarter results beat estimates. The bear case: the shares sit inside the target range.

Bull case

• Third-quarter results beat estimates. Revenue of $55.704 million beat the $55.404 million consensus, and the $0.08 loss per share beat the expected $0.13 loss, Benzinga reported on 2 November 2026. Revenue rose 14.5% with a 79.3% gross margin, per the company's 8-K exhibit.
• Procedure growth runs near 20%. US procedure volume rose about 19.5% in the third quarter, the 2 November 2026 release said. Active US physicians reached 1,770, up about 16%.
• The office payment is now final. The final 2027 Physician Fee Schedule pays about $19,441 nationally for code 27279 in the office from 1 January 2027, according to PainTEQ's 5 November 2026 release. At UBS on 10 November 2026, management said office and surgery-center growth adds to hospital volume. It said gross margin held steady in those settings because lower prices come with lower product costs.
• Hospital payments rose in October. New Medicare inpatient payment groups for complex pelvic fixation took effect on 1 October 2026. At UBS on 10 November 2026, management said they raise reimbursement by $20,000–$50,000 per case depending on complexity, and expects commercial payers to adopt them over about 12 months.
• The Onyx launch is on schedule. The alpha release of iFuse Granite Onyx began in October 2026, with a beta release planned for the fourth quarter and full launch for the first quarter of 2027, management said at UBS on 10 November 2026. It said early cases show higher selling prices and bring in surgeons who do not use Granite.
• Spending is growing more slowly. On 2 November 2026 the company cut 2026 operating expense growth guidance to about 10.5% from about 12.0%. Third-quarter adjusted earnings before interest, taxes, depreciation and amortization (EBITDA) were $3.0 million.
• The balance sheet funds the plan. Cash and short-term investments were $146.3 million at 30 September 2026, against $36.0 million of debt principal due from 2027 to 2029, per the third-quarter 10-Q.

Bear case

• The shares sit inside the target range. The $24.14 close on 12 November 2026 lies between TD Cowen's $23 target and BofA's $29 target. The two $26 targets from UBS and Needham, set on 3 November 2026, are close to the price.
• Gross margin faces a dip in 2027. At UBS on 10 November 2026, management said new launches and depreciation on Onyx instrument sets could pull gross margin to about 78% from the third quarter's 79.3%, before a longer-term goal near 80%.
• No 2027 guidance until February. Management declined to discuss 2027 at UBS on 10 November 2026. The February report will carry the first 2027 outlook.
• Lower prices dilute procedure growth. Third-quarter US revenue rose 13.9% while procedure volume rose about 19.5%, per the 2 November 2026 release. The gap reflects the shift toward lower-priced surgery-center and office cases.
• Insiders sold into the rise. SEC Form 4 filings show CEO Laura Francis sold 75,000 shares at $25.30, Chief Legal Officer Michael Pisetsky 36,241 shares at $24.80 and Chief Operating and Financial Officer Anshul Maheshwari 3,247 shares at $25.00, all on 4 November 2026. Director Jeffrey Dunn exercised options and sold 20,000 shares at $20.89 on 2 November 2026. Every sale was under a Rule 10b5-1 plan, and the filings show no purchases.
• The company still loses money. The third-quarter loss was $0.08 per share under generally accepted accounting principles, per the 2 November 2026 release. The profitability case rests on adjusted EBITDA.

Price setup

The shares closed at $24.14 on 12 November 2026, after a $25.60 close on 9 November 2026. The 52-week intraday high is $25.92, set on 4 November 2026, and the last close is 6.9% below it. The 52-week closing low is $11.61 on 11 May 2026.

In adjusted daily closes, the shares are up 27.5% over three months from the $18.93 close of 14 August 2026. The 50-day moving average is $20.28 and the 200-day is $16.72, both as of 12 November 2026. The last close is well above both.

The case turns on the post-report gain. The shares rose from the close before the 2 November 2026 report to the November highs, and the kill line sits at that pre-report close, just below the 50-day average. A return there would show the market giving back the whole response to the third-quarter beat and the final Medicare office rate.

Catalysts ahead

• Q4 2026 (est.): Onyx beta release, following the October 2026 alpha release. Shows whether the expansion beyond the pelvis is widening on schedule before full launch.
• Q1 2027 (est.): iFuse Granite Onyx full launch, which management guides to the first quarter of 2027. Shows whether Onyx reaches general availability on time, which the 2027 growth case depends on.
• ~22 February 2027 (est.): Fourth-quarter and full-year 2026 results; management said late February. Settles delivery against the $231–233 million 2026 outlook and the more than 20% fourth-quarter growth it implies, and sets the first 2027 guidance.
• ~15 April 2027 (est.): Possible information on the Medicare new technology add-on payment application for Onyx. An approval would take effect on 1 October 2027 and add hospital payment support for Onyx cases.

What would change the view

A daily close below $20.22, the 2 November 2026 close before the third-quarter report, which would erase the post-report gain; separately, a cut to the $231–233 million 2026 revenue outlook or full-year 2026 revenue below $231 million.

The risks this note tracks, each with what would confirm it:

• The fourth quarter falls short of the growth the 2026 outlook implies. Confirmed by: full-year 2026 revenue below $231 million in the late-February report, or a guidance cut before it.
• The shares trade inside the post-report target range, leaving little room for disappointment. Confirmed by: target cuts or downgrades citing valuation from UBS, Needham, TD Cowen or BofA Securities.
• Product launches compress gross margin more than management indicated. Confirmed by: 2027 guidance or quarterly results showing gross margin below the roughly 78% management cited at UBS on 10 November 2026.
• The shift to lower-priced surgery-center and office procedures keeps reducing revenue per procedure. Confirmed by: US revenue growth again trailing procedure volume growth by a wider gap than the third quarter's 13.9% against 19.5%.
• Medicare contractors decline to cover sacroiliac fusion in the office despite the new 2027 payment rate. Confirmed by: contractor coverage policies excluding the office setting, or management reporting little office volume in 2027 guidance.
• Insider supply weighs on the shares after the post-report rise. Confirmed by: further director or officer sales on SEC Form 4 after the 4 November 2026 sales, with no offsetting purchases.

What it trades with

SI-BONE trades as a small-cap medical device company. Its own news moves it more than broad markets do. The shares respond most to Medicare payment decisions for sacroiliac joint fusion, which also affect competitors such as PainTEQ. Spine and orthopedic device makers are the closest comparisons.